- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
The FDA has begun to regulate the market for obesity medications, reflecting a broader trend in pharmaceutical oversight.
1 report, 1 independent
Updated May 26
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The FDA has begun to regulate the market for obesity medications, reflecting a broader trend in pharmaceutical oversight.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Rhythm Pharmaceuticals' Setmelanotide was authorized for specific obesity cases by the FDA and European Commission.Sub-event
FDA regulates the market for obesity medications.1 source
Keep exploring
Part of
A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.Also in this story
- A partnership with BARDA has accelerated the development of SCY-247 for the company.
- A company plans to submit regulatory applications to the FDA, EMA, and Australian TGA.
- Approval leads to procurement process initiation.
- UroGen Pharma Ltd., headquartered in Princeton, is seeking FDA approval for its products for the U.S. market.
The entities involved
Related events
- A Patient Assistance Program has been established to cover prescription medications that have received FDA approval.
- The FDA is monitoring drug industry practices and pricing, utilizing studies published by JAMA.
- A study author is based in Johns Hopkins School of Medicine, and the research is connected to Baltimore, now involving the FDA for drug approval.
- The FDA regulates cosmetic ingredients used in the market.
- FDA clearance drives market expansion and coverage for NeurAxis, Inc.